Disclosure NewswireTMiCrowdNewswire - May 20, 2017
May 19, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring ProPetro Holding Corp (NYSE:PUMP) in real time and just received an alert that PUMP is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 4403900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $13.73. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net .
From August 2009 to April 2017, an aggregate amount of 26365585 shares of PUMP have been shorted for a total dollar value of $342752605. The PUMP SqueezeTrigger price of $13.73 is the volume weighted average price that all shorts are short in shares of PUMP. There is still approximately $61,134,940 of potential short covering in shares of PUMP.
Buyins.net has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.buyins.net .
ProPetro Holding Corp (NYSE:PUMP) – Animas Corporation, incorporated in July 1996, designs, develops, manufactures and sells external insulin pumps for people with diabetes. The Company is also engaged in supplying new pump placements in the United States. Products include the IR 1200, IR 1250 R1000 and IR 1000 pumps. The IR 1250 utilizes the IR 1200 platform but includes additional software that incorporates a food database of up to 500 items and tunes for alerts. During the year ended December 31, 2004, Animas was selling its pump products in Australia, Austria, Canada, the Czech Republic, France, Finland, Greece, Germany, Hungary, the Republic of Ireland, Israel, Italy, New Zealand, Spain, Sweden and the United Kingdom. The Company also provides ancillary supplies on an ongoing basis for patients using its pumps, including insulin cartridges, infusion sets, batteries, and various accessories. It provides education programs and services to people with diabetes.
Animas’s ezManager/ezManager Plus software package assists patients and their healthcare team with diabetes management. EzManager has two integrated software applications, one for Palm operating system (OS)-based handhelds and one for desktop computers. The PalmOS application allows users to calculate their carbohydrate intake based on a list of consumed foods and record numerous logs relevant to their diabetes. It also makes corrective recommendations based on the user’s input. The GlucoWatch Biographer, a product developed by Cygnus Inc. and obtained by Animas in its asset purchase of Cygnus in March 2005, is a non-invasive continuous glucose monitor, worn on the patient’s wrist, which provides blood glucose readings every 20 minutes. It utilizes an electric field to extract sodium ions. Other small molecules, including glucose, contained in interstitial fluid are swept through the skin with the sodium ions. The GlucoWatch Biographer also contains a glucose-oxidase electrochemical sensor to measure the glucose extracted through the skin. The second -generation GlucoWatch (G2) Biographer has a two-hour, warm-up time upon inserting a new AutoSensor.
In October 2004, the Company entered into license and development agreements with Debiotech for certain technology and intellectual property. Animas acquired the worldwide license to make, use and sell products utilizing the intellectual property portfolio owned by Debiotech relating to micro-pumps and micro-needles for use related to insulin administration and in-vivo glucose sensing. In December 2004, it received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the IR 1250 pump.
R1000/ IR 1000 Pumps
The Company’s initial product, the R1000 insulin pump was introduced to the market during the year ended December 31, 2000. Its second-generation product, the IR 1000, received FDA clearance and was introduced to the market during the year ended December 31, 2002. The IR 1000 uses the same platform as the R1000, and provides infrared (IR) download of pump history and an improved user interface. Animas will continue to offer the IR 1000 internationally and to patients who are insulin-resistant and/or prefer the greater insulin capacity of the IR 1000 (300 units) versus the IR 1200 (200 units).
IR 1200 Insulin Pump
The IR 1200 pumps (and its successor-generation pump, the IR 1250 pumps) weigh approximately 3.2 ounces. It is 25% smaller than its predecessor product, the IR 1000. It allows basal insulin to be dosed in extremely small increments of one quarter of a microliter. The IR 1200 has a large screen and its menu driven operation makes insulin dose-related calculations easier. An intuitive user interface reduces the time it takes to teach patients how to use the pump. It uses a AA lithium or alkaline battery. The IR 1200 also detects a variety of conditions, including occlusions (blockages) in the infusion set and malfunctions in the electronics, microprocessor or mechanical systems. It has triple hermetically sealed housings, one each for the battery, the cartridge and the electronics. This triple .
The SqueezeTrigger database of billions of short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor – Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new “Fair Market Making Requirements”
Naked Shorts (RegSho) – Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
Earnings – Predicts probability, price move and length of move before and after all US stock earnings reports
Seasonality – Predicts probability, price move and length of move based on exact time of year for all US stocks
Group Correlation – Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups
SqueezeTrigger – Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Valuation – Tracks all known valuation models and applies them.
GATS – Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies.
PatternScan – Automates tracking of every technical pattern and predicts next move in stocks.
Insider – Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders
Events – Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Tom Ronk, CEO